
CymaBay Therapeutics (CBAY) Stock Forecast & Price Target
CymaBay Therapeutics (CBAY) Analyst Ratings
Bulls say
CymaBay Therapeutics is poised for success due to their strong pipeline of potential treatments for liver and chronic diseases, including the promising seladelpar and MBX-2982. Positive results and planned partnerships for seladelpar, along with a favorable market size for PBC treatment and supportive recommendations from key opinion leaders, suggest that CBAY has the potential for significant growth. However, risks in commercial and regulatory aspects, as well as the number of patients required for their studies, could present challenges for the company.
Bears say
CymaBay Therapeutics is facing significant commercial and competitive risks with its lead product candidates, seladelpar and MBX-2982, in clinical development for liver diseases with high unmet need. The company's cash balance of $438.8 million may only support operations until the first half of 2026, raising concerns about its long-term sustainability and potential need for additional fundraising. In addition, the recent failure of MBX-2982 in a Phase 2a study for type 1 diabetes may further impact investor sentiment and future potential market opportunities for the company's pipeline.
This aggregate rating is based on analysts' research of CymaBay Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
CymaBay Therapeutics (CBAY) Analyst Forecast & Price Prediction
Start investing in CymaBay Therapeutics (CBAY)
Order type
Buy in
Order amount
Est. shares
0 shares